(123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis
Cardiac amyloidosis is a rare disorder, but it may lead to potentially life-threatening restrictive cardiomyopathy. Cardiac manifestations frequently occur in primary amyloidosis (AL) and familial amyloidosis (ATTR), but are uncommon in secondary amyloidosis (AA). Echocardiography is the method of c...
Gespeichert in:
Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2012-10, Vol.39 (10), p.1609-1617 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1617 |
---|---|
container_issue | 10 |
container_start_page | 1609 |
container_title | European journal of nuclear medicine and molecular imaging |
container_volume | 39 |
creator | Noordzij, Walter Glaudemans, Andor W J M van Rheenen, Ronald W J Hazenberg, Bouke P C Tio, René A Dierckx, Rudi A J O Slart, Riemer H J A |
description | Cardiac amyloidosis is a rare disorder, but it may lead to potentially life-threatening restrictive cardiomyopathy. Cardiac manifestations frequently occur in primary amyloidosis (AL) and familial amyloidosis (ATTR), but are uncommon in secondary amyloidosis (AA). Echocardiography is the method of choice for assessing cardiac amyloidosis. Amyloid deposits impair the function of sympathetic nerve endings. Disturbance of myocardial sympathetic innervations may play an important role in the remodelling process. (123)I-MIBG can detect these innervation changes.
Patients with biopsy-proven amyloidosis underwent general work-up, echocardiography and (123)I-MIBG scintigraphy. Left ventricular internal dimensions and wall thickness were measured, and highly refractile cardiac echoes (sparkling) were analysed. Early (15 min) and late (4 h) heart-to-mediastinum ratio (HMR) and wash-out rate were determined after administration of MIBG.
Included in the study were 61 patients (30 women and 31 men; mean age 62 years; 39 AL, 11 AA, 11 ATTR). Echocardiographic parameters were not significantly different between the groups. Sparkling was present in 72 % of ATTR patients, in 54 % of AL patients and in 45 % of AA patients. Mean late HMR in all patients was 2.3 ± 0.75, and the mean wash-out rate was 8.6 ± 14 % (the latter not significantly different between the patient groups). Late HMR was significantly lower in patients with echocardiographic signs of amyloidosis than in patients without (2.0 ± 0.70 versus 2.8 ± 0.58, p < 0.001). Wash-out rates were significantly higher in these patients (-3.3 ± 9.9 % vs. 17 ± 10 %, p < 0.001). In ATTR patients without echocardiographic signs of amyloidosis, HMR was lower than in patients with the other types (2.0 ± 0.59 vs. 2.9 ± 0.50, p = 0.007).
MIBG HMR is lower and wash-out rate is higher in patients with echocardiographic signs of amyloidosis. Also, (123)I-MIBG scintigraphy can detect cardiac denervation in ATTR patients before signs of amyloidosis are evident on echocardiography. |
doi_str_mv | 10.1007/s00259-012-2187-8 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1080882826</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1080882826</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-e0646889fbe804fed75141308d589b1cde630541d27a52237b73872889cc20243</originalsourceid><addsrcrecordid>eNo1kMtOwzAURC0kREvhA9ggL8vCcH3zsLNEFY9KldjAOnLim2KUxCFOKsLXE6llNYs5M9IMYzcS7iWAeggAmGQCJAqUWgl9xpYylZlQoLMFuwzhC0Bq1NkFWyBqSCHJluxnLTG624qdKaiuyfKGBuO89QW1v1O9H03rrGuJV77nwydxOph6NIPzLfcVL01vnSl5mJrOzPbgSm6ppf5wRFzLyfT1xMNg9sRNM9XeWR9cuGLnlakDXZ90xT6en943r2L39rLdPO5EJzEdBEEap1pnVUEa4oqsSmQsI9A20VkhS0tpBEksLSqTIEaqUJFWOCfKEgHjaMXWx96u998jhSFvXCjnraYlP4ZcggY934LpjN6e0LFoyOZd7xrTT_n_W9Efk7BrBQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1080882826</pqid></control><display><type>article</type><title>(123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Noordzij, Walter ; Glaudemans, Andor W J M ; van Rheenen, Ronald W J ; Hazenberg, Bouke P C ; Tio, René A ; Dierckx, Rudi A J O ; Slart, Riemer H J A</creator><creatorcontrib>Noordzij, Walter ; Glaudemans, Andor W J M ; van Rheenen, Ronald W J ; Hazenberg, Bouke P C ; Tio, René A ; Dierckx, Rudi A J O ; Slart, Riemer H J A</creatorcontrib><description>Cardiac amyloidosis is a rare disorder, but it may lead to potentially life-threatening restrictive cardiomyopathy. Cardiac manifestations frequently occur in primary amyloidosis (AL) and familial amyloidosis (ATTR), but are uncommon in secondary amyloidosis (AA). Echocardiography is the method of choice for assessing cardiac amyloidosis. Amyloid deposits impair the function of sympathetic nerve endings. Disturbance of myocardial sympathetic innervations may play an important role in the remodelling process. (123)I-MIBG can detect these innervation changes.
Patients with biopsy-proven amyloidosis underwent general work-up, echocardiography and (123)I-MIBG scintigraphy. Left ventricular internal dimensions and wall thickness were measured, and highly refractile cardiac echoes (sparkling) were analysed. Early (15 min) and late (4 h) heart-to-mediastinum ratio (HMR) and wash-out rate were determined after administration of MIBG.
Included in the study were 61 patients (30 women and 31 men; mean age 62 years; 39 AL, 11 AA, 11 ATTR). Echocardiographic parameters were not significantly different between the groups. Sparkling was present in 72 % of ATTR patients, in 54 % of AL patients and in 45 % of AA patients. Mean late HMR in all patients was 2.3 ± 0.75, and the mean wash-out rate was 8.6 ± 14 % (the latter not significantly different between the patient groups). Late HMR was significantly lower in patients with echocardiographic signs of amyloidosis than in patients without (2.0 ± 0.70 versus 2.8 ± 0.58, p < 0.001). Wash-out rates were significantly higher in these patients (-3.3 ± 9.9 % vs. 17 ± 10 %, p < 0.001). In ATTR patients without echocardiographic signs of amyloidosis, HMR was lower than in patients with the other types (2.0 ± 0.59 vs. 2.9 ± 0.50, p = 0.007).
MIBG HMR is lower and wash-out rate is higher in patients with echocardiographic signs of amyloidosis. Also, (123)I-MIBG scintigraphy can detect cardiac denervation in ATTR patients before signs of amyloidosis are evident on echocardiography.</description><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-012-2187-8</identifier><identifier>PMID: 22806059</identifier><language>eng</language><publisher>Germany</publisher><subject>3-Iodobenzylguanidine ; Aged ; Amyloidosis - complications ; Amyloidosis - diagnostic imaging ; Cardiomyopathies - diagnostic imaging ; Cardiomyopathies - etiology ; Female ; Gated Blood-Pool Imaging ; Heart - innervation ; Humans ; Male ; Middle Aged ; Myocardial Perfusion Imaging ; Nerve Endings - diagnostic imaging ; Radiopharmaceuticals ; Sympathetic Nervous System - diagnostic imaging ; Ultrasonography</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2012-10, Vol.39 (10), p.1609-1617</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22806059$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Noordzij, Walter</creatorcontrib><creatorcontrib>Glaudemans, Andor W J M</creatorcontrib><creatorcontrib>van Rheenen, Ronald W J</creatorcontrib><creatorcontrib>Hazenberg, Bouke P C</creatorcontrib><creatorcontrib>Tio, René A</creatorcontrib><creatorcontrib>Dierckx, Rudi A J O</creatorcontrib><creatorcontrib>Slart, Riemer H J A</creatorcontrib><title>(123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Cardiac amyloidosis is a rare disorder, but it may lead to potentially life-threatening restrictive cardiomyopathy. Cardiac manifestations frequently occur in primary amyloidosis (AL) and familial amyloidosis (ATTR), but are uncommon in secondary amyloidosis (AA). Echocardiography is the method of choice for assessing cardiac amyloidosis. Amyloid deposits impair the function of sympathetic nerve endings. Disturbance of myocardial sympathetic innervations may play an important role in the remodelling process. (123)I-MIBG can detect these innervation changes.
Patients with biopsy-proven amyloidosis underwent general work-up, echocardiography and (123)I-MIBG scintigraphy. Left ventricular internal dimensions and wall thickness were measured, and highly refractile cardiac echoes (sparkling) were analysed. Early (15 min) and late (4 h) heart-to-mediastinum ratio (HMR) and wash-out rate were determined after administration of MIBG.
Included in the study were 61 patients (30 women and 31 men; mean age 62 years; 39 AL, 11 AA, 11 ATTR). Echocardiographic parameters were not significantly different between the groups. Sparkling was present in 72 % of ATTR patients, in 54 % of AL patients and in 45 % of AA patients. Mean late HMR in all patients was 2.3 ± 0.75, and the mean wash-out rate was 8.6 ± 14 % (the latter not significantly different between the patient groups). Late HMR was significantly lower in patients with echocardiographic signs of amyloidosis than in patients without (2.0 ± 0.70 versus 2.8 ± 0.58, p < 0.001). Wash-out rates were significantly higher in these patients (-3.3 ± 9.9 % vs. 17 ± 10 %, p < 0.001). In ATTR patients without echocardiographic signs of amyloidosis, HMR was lower than in patients with the other types (2.0 ± 0.59 vs. 2.9 ± 0.50, p = 0.007).
MIBG HMR is lower and wash-out rate is higher in patients with echocardiographic signs of amyloidosis. Also, (123)I-MIBG scintigraphy can detect cardiac denervation in ATTR patients before signs of amyloidosis are evident on echocardiography.</description><subject>3-Iodobenzylguanidine</subject><subject>Aged</subject><subject>Amyloidosis - complications</subject><subject>Amyloidosis - diagnostic imaging</subject><subject>Cardiomyopathies - diagnostic imaging</subject><subject>Cardiomyopathies - etiology</subject><subject>Female</subject><subject>Gated Blood-Pool Imaging</subject><subject>Heart - innervation</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myocardial Perfusion Imaging</subject><subject>Nerve Endings - diagnostic imaging</subject><subject>Radiopharmaceuticals</subject><subject>Sympathetic Nervous System - diagnostic imaging</subject><subject>Ultrasonography</subject><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kMtOwzAURC0kREvhA9ggL8vCcH3zsLNEFY9KldjAOnLim2KUxCFOKsLXE6llNYs5M9IMYzcS7iWAeggAmGQCJAqUWgl9xpYylZlQoLMFuwzhC0Bq1NkFWyBqSCHJluxnLTG624qdKaiuyfKGBuO89QW1v1O9H03rrGuJV77nwydxOph6NIPzLfcVL01vnSl5mJrOzPbgSm6ppf5wRFzLyfT1xMNg9sRNM9XeWR9cuGLnlakDXZ90xT6en943r2L39rLdPO5EJzEdBEEap1pnVUEa4oqsSmQsI9A20VkhS0tpBEksLSqTIEaqUJFWOCfKEgHjaMXWx96u998jhSFvXCjnraYlP4ZcggY934LpjN6e0LFoyOZd7xrTT_n_W9Efk7BrBQ</recordid><startdate>201210</startdate><enddate>201210</enddate><creator>Noordzij, Walter</creator><creator>Glaudemans, Andor W J M</creator><creator>van Rheenen, Ronald W J</creator><creator>Hazenberg, Bouke P C</creator><creator>Tio, René A</creator><creator>Dierckx, Rudi A J O</creator><creator>Slart, Riemer H J A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201210</creationdate><title>(123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis</title><author>Noordzij, Walter ; Glaudemans, Andor W J M ; van Rheenen, Ronald W J ; Hazenberg, Bouke P C ; Tio, René A ; Dierckx, Rudi A J O ; Slart, Riemer H J A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-e0646889fbe804fed75141308d589b1cde630541d27a52237b73872889cc20243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>3-Iodobenzylguanidine</topic><topic>Aged</topic><topic>Amyloidosis - complications</topic><topic>Amyloidosis - diagnostic imaging</topic><topic>Cardiomyopathies - diagnostic imaging</topic><topic>Cardiomyopathies - etiology</topic><topic>Female</topic><topic>Gated Blood-Pool Imaging</topic><topic>Heart - innervation</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myocardial Perfusion Imaging</topic><topic>Nerve Endings - diagnostic imaging</topic><topic>Radiopharmaceuticals</topic><topic>Sympathetic Nervous System - diagnostic imaging</topic><topic>Ultrasonography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Noordzij, Walter</creatorcontrib><creatorcontrib>Glaudemans, Andor W J M</creatorcontrib><creatorcontrib>van Rheenen, Ronald W J</creatorcontrib><creatorcontrib>Hazenberg, Bouke P C</creatorcontrib><creatorcontrib>Tio, René A</creatorcontrib><creatorcontrib>Dierckx, Rudi A J O</creatorcontrib><creatorcontrib>Slart, Riemer H J A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Noordzij, Walter</au><au>Glaudemans, Andor W J M</au><au>van Rheenen, Ronald W J</au><au>Hazenberg, Bouke P C</au><au>Tio, René A</au><au>Dierckx, Rudi A J O</au><au>Slart, Riemer H J A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>(123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2012-10</date><risdate>2012</risdate><volume>39</volume><issue>10</issue><spage>1609</spage><epage>1617</epage><pages>1609-1617</pages><eissn>1619-7089</eissn><abstract>Cardiac amyloidosis is a rare disorder, but it may lead to potentially life-threatening restrictive cardiomyopathy. Cardiac manifestations frequently occur in primary amyloidosis (AL) and familial amyloidosis (ATTR), but are uncommon in secondary amyloidosis (AA). Echocardiography is the method of choice for assessing cardiac amyloidosis. Amyloid deposits impair the function of sympathetic nerve endings. Disturbance of myocardial sympathetic innervations may play an important role in the remodelling process. (123)I-MIBG can detect these innervation changes.
Patients with biopsy-proven amyloidosis underwent general work-up, echocardiography and (123)I-MIBG scintigraphy. Left ventricular internal dimensions and wall thickness were measured, and highly refractile cardiac echoes (sparkling) were analysed. Early (15 min) and late (4 h) heart-to-mediastinum ratio (HMR) and wash-out rate were determined after administration of MIBG.
Included in the study were 61 patients (30 women and 31 men; mean age 62 years; 39 AL, 11 AA, 11 ATTR). Echocardiographic parameters were not significantly different between the groups. Sparkling was present in 72 % of ATTR patients, in 54 % of AL patients and in 45 % of AA patients. Mean late HMR in all patients was 2.3 ± 0.75, and the mean wash-out rate was 8.6 ± 14 % (the latter not significantly different between the patient groups). Late HMR was significantly lower in patients with echocardiographic signs of amyloidosis than in patients without (2.0 ± 0.70 versus 2.8 ± 0.58, p < 0.001). Wash-out rates were significantly higher in these patients (-3.3 ± 9.9 % vs. 17 ± 10 %, p < 0.001). In ATTR patients without echocardiographic signs of amyloidosis, HMR was lower than in patients with the other types (2.0 ± 0.59 vs. 2.9 ± 0.50, p = 0.007).
MIBG HMR is lower and wash-out rate is higher in patients with echocardiographic signs of amyloidosis. Also, (123)I-MIBG scintigraphy can detect cardiac denervation in ATTR patients before signs of amyloidosis are evident on echocardiography.</abstract><cop>Germany</cop><pmid>22806059</pmid><doi>10.1007/s00259-012-2187-8</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | EISSN: 1619-7089 |
ispartof | European journal of nuclear medicine and molecular imaging, 2012-10, Vol.39 (10), p.1609-1617 |
issn | 1619-7089 |
language | eng |
recordid | cdi_proquest_miscellaneous_1080882826 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | 3-Iodobenzylguanidine Aged Amyloidosis - complications Amyloidosis - diagnostic imaging Cardiomyopathies - diagnostic imaging Cardiomyopathies - etiology Female Gated Blood-Pool Imaging Heart - innervation Humans Male Middle Aged Myocardial Perfusion Imaging Nerve Endings - diagnostic imaging Radiopharmaceuticals Sympathetic Nervous System - diagnostic imaging Ultrasonography |
title | (123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T21%3A30%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=(123)I-Labelled%20metaiodobenzylguanidine%20for%20the%20evaluation%20of%20cardiac%20sympathetic%20denervation%20in%20early%20stage%20amyloidosis&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Noordzij,%20Walter&rft.date=2012-10&rft.volume=39&rft.issue=10&rft.spage=1609&rft.epage=1617&rft.pages=1609-1617&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-012-2187-8&rft_dat=%3Cproquest_pubme%3E1080882826%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1080882826&rft_id=info:pmid/22806059&rfr_iscdi=true |